Intarcia Therapeutics, Inc. Enrolls First Patients in "Freedom" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3/21/2013 11:24:10 AM
More...
|
Intarcia Therapeutics, Inc. Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2/5/2013 7:19:41 AM
More...
|
Intarcia Therapeutics, Inc. Secures $210 Million Financing to Fund Its Global Phase 3 Program
11/15/2012 9:06:52 AM
More...
|
Intarcia Therapeutics, Inc. Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD
10/3/2012 10:15:19 AM
More...
|
Intarcia Therapeutics, Inc. to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD
9/28/2012 10:40:13 AM
More...
|
Intarcia Therapeutics, Inc. Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
4/2/2012 7:58:02 AM
More...
|
Intarcia Therapeutics, Inc. Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer
3/27/2012 11:47:06 AM
More...
|
Intarcia Therapeutics, Inc. and Quintiles, Inc. (QTRN) Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
12/13/2011 7:55:32 AM
More...
|
Intarcia Therapeutics, Inc. and Quintiles, Inc. (QTRN) Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes
10/24/2011 6:18:37 AM
More...
|
Intarcia Therapeutics, Inc. Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
9/14/2011 11:34:14 AM
More...
|
|